Clin2
NCT05371483Possibly a fitEnrolling by invitation

Study effects of narcolepsy and hypersomnia treatments on brain and heart

NarcolepsyIdiopathic Hypersomnia

Part of Brain & nervous system, Mental health clinical trials.

This study looks at how narcolepsy or idiopathic hypersomnia affects thinking and cardiovascular health, and how usual treatment medications may change those outcomes. It may help researchers understand risks and benefits of common hypersomnia therapies.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
100 people
Ages
18 years to 75 years
Study type
Observational

Who can take part

  • You have been diagnosed with narcolepsy or idiopathic hypersomnia by a sleep specialist
  • You are age 18 to 75, and your body mass index (BMI) is between 18 and 40
  • You are already prescribed one of the study’s usual hypersomnia medicines (like modafinil, pitolisant, solriamfetol, or oxybate types)
  • You can delay starting or changing that medication until after the initial baseline checkups (or stay on a stable dose if you’re switching in a specific way)
  • No medication changes in the last 45 days
  • No pregnancy or breastfeeding

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05837091Recruiting· Phase 4
Low-dose sodium oxybate for idiopathic hypersomnia sleepiness

This trial tests whether low-dose sodium oxybate can improve symptoms in adults with idiopathic hypersomnia, a condition that causes excessive sleepiness. You’d likely be asked to pause this standard treatment briefly while baseline testing is completed, and you’d use reliable contraception during and after the study drug.

Phoenix, Arizona
NCT07077278Not yet recruiting· Phase 4
Low sodium oxybate for hypersomnia with POTS

This study tests whether low sodium oxybate, a medication that improves alertness, can help reduce symptoms like dizziness and fatigue in people who have both idiopathic hypersomnia and POTS. You would stay on your current daytime medications, but some heart-related drugs may be paused temporarily before tests.

NCT06457945Recruiting
Mind-wandering and daydreaming in narcolepsy and hypersomnia

This study looks at whether people with narcolepsy or idiopathic hypersomnia have different patterns of daydreaming and mind-wandering compared to others with sleepiness but no clear diagnosis. It helps understand how certain brain states during sleep might affect waking thoughts.

Lyon
NCT06484348Recruiting
How food affects sleepiness in narcolepsy and hypersomnia

This study explores how what you eat affects your sleepiness and nighttime sleep quality. Researchers want to learn more about these links in people with narcolepsy type 1 or idiopathic hypersomnia.

Clermont-Ferrand
NCT07675135Recruiting· Phase 3
Testing a new narcolepsy drug for excessive daytime sleepiness

This study tests a new medicine, HBS-301, for people with narcolepsy type 1 or type 2 who still have excessive daytime sleepiness. If you take other medications for sleepiness or mood, they must be stable for at least 3 months, and you cannot take some as-needed sleepiness medicines.

Birmingham, Alabama
NCT07500090Recruiting· Phase 3
Study of HBS-301 for idiopathic hypersomnia

This trial tests a new medication, HBS-301, in people with idiopathic hypersomnia (a condition causing excessive sleepiness without clear cause). It aims to see if the drug improves wakefulness and is safe.

Birmingham, Alabama

Hear when a new Narcolepsy trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.